Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

With CONCORDBIO's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 6.968000
forwardPE 28.732187
debtToEquity 0.088000
earningsGrowth -0.341000
revenueGrowth -0.204000
grossMargins 0.642020
operatingMargins 0.283740
trailingEps 30.950000
forwardEps 43.432130

CONCORDBIO's current ratio of 6.968 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. CONCORDBIO's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
CONCORDBIO's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Concord Biotech Limited's low growth in earnings and revenue indicates that profits could shrink. This signals potential financial difficulties for the company, suggesting that its profitability might be under pressure.
With positive gross and operating margins, Concord Biotech Limited demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
CONCORDBIO's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for CONCORDBIO's financial growth.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

The present price of CONCORDBIO in relation to its projections indicates a lack of clear risks or opportunities. This balanced situation suggests that investors may find it prudent to wait for further signals before making significant moves in the stock.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


CONCORDBIO has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view CONCORDBIO as a reliable choice for their money, offering a promising avenue for future growth and financial gains.